Welcome
Support Centre
09 January 2009 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
National randomised trial of hormone replacement therapy (HRT) in women with a history of early stage breast cancer
ISRCTN ISRCTN29941643
ClinicalTrials.gov identifier NCT00079248
Public title National randomised trial of hormone replacement therapy (HRT) in women with a history of early stage breast cancer
Scientific title
Acronym HRT
Serial number at source N/A
Study hypothesis Not provided at time of registration
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Breast
Participants - inclusion criteria 1. Patients must have had proven stage I/II breast cancer with no clinical evidence of recurrence since diagnosis
2. Have been given a patient information pack
3. Be postmenopausal as defined by:
a. Having been amenorrhoeic for at least 6 months (including women who have had radiation or chemical induced ovarian suppression) irrespective of menopausal status at time of diagnosis
b. Having received surgical bilateral oophorectomy
c. Be experiencing vasomotor symptoms (i.e. hot flushes or night sweats) with or without vaginal dryness.

All such women are eligible irrespective of current/previous treatment for breast cancer.
Participants - exclusion criteria Not provided at time of registration
Anticipated start date 01/08/2003
Anticipated end date 01/08/2006
Status of trial Completed
Patient information material
Target number of participants 60
Interventions Patients will be randomised to receive:
1. HRT
2. No HRT (advice about non-hormonal alternatives)
Primary outcome measure(s) Not provided at time of registration
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Cancer Research UK
Trial website
Publications
Contact name Ms  Jenni  Parmar
  Address Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU)
Section of Epidemiology
Brookes Lawley Building
Cotswold Road
  City/town Sutton, Surrey
  Zip/Postcode SM2 5NG
  Country United Kingdom
  Tel +44 (0)20 8722 4373
  Fax +44 (0)20 8770 7876
  Email HRT-icrctsu@icr.ac.uk
Sponsor Individual Sponsor
  Address Mr Nigel Sacks
The Royal Marsden NHS Trust
  City/town London
  Zip/Postcode SM2 5NG
  Country United Kingdom
  Tel +44 (0) 20 8722 4373
  Fax +44 (0) 20 8770 7876
  Email Claire.Dawson@icr.ac.uk
  Sponsor website: http://www.cancer.org.uk
Date applied 01/07/2001
Last edited 20/02/2006
Date ISRCTN assigned 01/07/2001
Submit your trial protocol Top studies in medical research Submit to Trials journal
© ISRCTN


BioMed Central